11th week of 2014 patent applcation highlights part 48 |
Patent application number | Title | Published |
20140073534 | DETECTION OF TARGET NUCLEIC ACID SEQUENCES BY PO CLEAVAGE AND HYBRIDIZATION - The present invention relates to the detection of a target nucleic acid sequence by a POCH (PO Cleavage and Hybridization) assay on a solid substrate. The present invention detects the target nucleic acid sequence by use of in which the PO (Probing Oligonucleotide) hybridized with the target nucleic acid sequence is cleaved and the cleavage of the PO is detected by hybridization with the CO (Capturing Oligonucleotide). In the present invention, an uncleaved PO is hybridized with the CO immobilized onto the solid substrate. The designs of the PO and the CO are convenient and the optimization of reaction conditions is routinely easy in the present invention. Where the detection of signal on the solid substrate is continuously performed along with repetition of cleavage of the POs in the present invention, the number of the POs cleaved is increased upon the repetition number of the cleavage reaction and the signal is changed in parallel with the number of the POs cleaved. Then, the target nucleic acid sequence can be detected in a real-time manner. In contrast, the change of the signal is not observed in the absence of the target nucleic acid sequence. | 2014-03-13 |
20140073535 | MOLECULAR MARKERS IN PROSTATE CANCER - The present invention relates to methods for diagnosing prostate cancer and especially diagnosing LG, HG, PrCa Met and CRPC. Specifically, the present invention relates to methods for in vitro diagnosing prostate cancer in a human individual comprising: 1) determining the expression of one or more genes chosen from the group consisting of ACSM1, ALDH3B2, CGREF1, COMP, C19orf48, DLX1, GLYATL1, MS4A8B, NKAIN1, PPFIA2, PTPRT, TDRD1 and/or UGT2B15; | 2014-03-13 |
20140073536 | METHODS AND COMPOSITIONS FOR DETECTING NON-HEMATOPOIETIC CELLS FROM A BLOOD SAMPLE - The present invention recognizes that diagnosis and prognosis of many conditions can depend on the enrichment of rare cells, especially tumor cells, from a complex fluid sample such as a blood sample. In particular, the present invention is directed to methods and compositions for detecting a non-hematopoietic cell, e.g., a non-hematopoietic tumor cell, in a blood sample via, inter alia, removing red blood cells (RBCs) from a blood sample using a non-centrifugation procedure, removing white blood cells (WBCs) from said blood sample to enrich a non-hematopoietic cell, if any, from said blood sample; and assessing the presence, absence and/or amount of said enriched non-hematopoietic cell. | 2014-03-13 |
20140073537 | Sealant Compositions and Methods of Use - Of the many methods and compositions provided herein, one method includes a method comprising introducing a sealant composition into a well bore that penetrates a subterranean formation, wherein the sealant composition comprises a base fluid, a binder material, and a filler material; and allowing the sealant composition to form a cohesive sealant. One composition provided herein includes a sealant composition comprising a base fluid, a binder material, and a filler material, wherein the sealant composition will form a cohesive sealant. | 2014-03-13 |
20140073538 | Fluid Loss Control Composition and Method of Using the Same - Fluid loss materials including carboxymethylcellulose and zirconium-based crosslinkers may be employed as fluid loss materials in methods of treating subterranean formations. One method includes providing a treatment fluid including carboxymethylcellulose (CMC) and a crosslinker including zirconium, wherein the carboxymethylcellulose has a degree of substitution in a range of from about 0.5 to about 2.5, wherein the crosslinker including zirconium includes one selected from the group consisting of ammonium zirconium fluoride, zirconium 2-ethylhexanoate, zirconium acetate, zirconium neodecanoate, zirconium acetylacetonate, tetrakis(triethanolamine) zirconate, zirconium carbonate, ammonium zirconium carbonate, zirconyl ammonium carbonate, zirconium complex of hydroxyethyl glycine, zirconium malonate, zirconium propionate, zirconium lactate, zirconium acetate lactate, and zirconium tartrate, and placing the treatment fluid in a subterranean formation, wherein the treatment fluid controls fluid loss in a permeable portion of the subterranean formation penetrated by a wellbore. | 2014-03-13 |
20140073539 | AQUEOUS DISPERSION AND ADDITIVES FOR FRACTURING WORK - The aqueous dispersion of the present invention is an aqueous dispersion in which a biodegradable resin composition (C) in the form of a fine solid is dispersed in an aqueous medium, and the biodegradable resin composition (C) comprises a copolymer (A) comprising a constituent unit (a-1) derived from a polyvalent carboxylic acid and a constituent unit (a-2) derived from a hydroxycarboxylic acid, and a biodegradable resin (B), and wherein the mass composition ratio [(A)/(B)] of the copolymer (A) to the biodegradable resin (B) is 1/99 to 100/0 provided that the total amount of the copolymer (A) and the biodegradable resin (B) is 100. | 2014-03-13 |
20140073540 | ACID-IN-OIL EMULSION COMPOSITIONS AND METHODS FOR TREATING HYDROCARBON-BEARING FORMATIONS - Disclosed herein is an acid-in-oil emulsion composition comprising an emulsifying agent; a dispersion agent; a base oil; and an acid, wherein the acid-in-oil emulsion composition is substantially devoid of priority pollutants. Disclosed herein too is a method for treating a hydrocarbon-bearing formation comprising blending an emulsifying agent, a base oil and an acid to produce an acid-in-oil emulsion, the acid-in-oil emulsion being substantially devoid of priority pollutants; and discharging the acid-in-oil emulsion into a downhole hydrocarbon-bearing well formation, where the acid-in-oil emulsion is operative to stimulate hydrocarbon production. | 2014-03-13 |
20140073541 | SURFACTANTS FOR ENHANCED OIL RECOVERY - Surfactant compositions useful for oil recovery comprise from 10 to 80 wt. % of a prapoxylated C12-C20 alcohol sulfate, from 10 to 80 wt. % of a C12-C20 internal olefin sulfonate, and from 0.1 to 10 wt. % of an ethoxylated C4-C12 alcohol sulfate. A minor proportion of the ethoxylated alcohol sulfate reduces or eliminates the need to rely on costly cosolvents for achieving good performance in enhanced oil recovery processes. Low interfaoial tensions and low microemulsion viscosities can be achieved when the ethoxylated alcohol sulfate accompanies the propoxytated alcohol sulfate and internal olefin sulfonate. Aqueous concentrates comprising water and the surfactant compositions described above are also disclosed. Dilution of the surfactant composition or aqueous concentrate with water or brine to the desired anionic actives level provides an injectable composition useful for EOR applications. Stable, low-viscosity oil-in-water microemulsions comprising crude oil, water, and the surfactant compositions are also disclosed. | 2014-03-13 |
20140073542 | ANTIFOAM ADDITIVES FOR USE IN LOW VISCOSITY APPLICATIONS - A lubricant composition comprising a major amount of a base oil having a kinematic viscosity between 2 and 8 cSt at 100° C. and a minor amount of an additive composition represented by formula IV: | 2014-03-13 |
20140073543 | Stabilized Blends Containing Friction Modifiers - The present invention relates to functional fluid compositions containing friction modifiers, and specifically stable compositions containing friction modifiers with limited solubility in and/or limited compatibility with the functional fluids with which they are used. In particular the present invention deals with functional fluids used in internal combustion engines, such as engine oils, and friction modifiers derived from hydroxy-carboxylic acids, where the friction modifier is present in the functional fluid composition at levels that would otherwise cause the composition to be unstable and/or hazy. | 2014-03-13 |
20140073544 | Low VOC Composition To Remove Graffiti - A Low-VOC, water-based graffiti cleaner containing water, Glycol Ether EB, Acetone, DBE, Acetic acid, and a small amount of fragrance. The VOC content of this composition is less than or equal to 15.5%. | 2014-03-13 |
20140073545 | METHOD FOR MAKING AND USING A STABLE CLEANING COMPOSITION - A method for preparing an emulsion cleaning composition that is resistant to separation upon exposure to depressed and elevated temperatures and which exhibits a persistent peroxide content comprises preparing an organic portion and an oxidant portion and then combining the organic portion and the oxidant portion under mixing to make the emulsion. The organic portion comprises an organic solvent, and emulsifier and a cleaner surfactant. The oxidant portion comprises an oxidizing compound activator and a peroxide generator. The emulsion cleaning composition is useful for removing petroleum distillate residue from metal surfaces such as refinery surfaces. | 2014-03-13 |
20140073546 | DRAIN FORMULATION FOR ENHANCED HAIR DISSOLUTION - The invention relates to drain cleaning compositions including relatively high concentrations of a hypochlorite oxidizing agent and a hydroxide (e.g., 4 to 12% and 2.5 to 10%, respectively. The composition further includes a surfactant (e.g., a surfactant blend, water, and exhibits a very high pH (e.g., at least 13). The composition is monophasic, even at high oxidizing and hydroxide concentrations. The surfactant may include a blend of an uncharged surfactant (e.g., an amphoteric surfactant or nonionic surfactant) and a charged surfactant (e.g., anionic, cationic, or a surfactant that becomes so under the high pH conditions of the composition). The ratio of charged to uncharged surfactant may be at least 1:10, e.g., from 1:10 to about 1:50. | 2014-03-13 |
20140073547 | DETERGENT COMPOSITION COMPRISING PEPTIDOGLYCAN-DIGESTING ENZYME - A detergent composition containing: (a) peptidoglycan-digesting enzyme having an amino acid sequence identity of at least 80% to the amino acid SEQ ID NO: 1, 2 or 3; (b) detersive surfactant; and a detergent ingredient selected from the group consisting of: (c) perfume microcapsule; (d) a builder system that is: (i) substantially free of phosphate builder; (ii) substantially free of zeolite builder; and (iii) optionally, substantially free of silicate salt; (e) protease system comprising: (i) protease; and (ii) stabiliser system selected from the group consisting of: borate, polyol, 4-formylphenylboronic acid, encapsulating material, and any mixture thereof; and (f) any mixture thereof. | 2014-03-13 |
20140073548 | DETERGENT COMPOSITIONS CONTAINING BACILLUS SP. MANNANASE AND METHODS OF USE THEREOF - The present compositions and methods relate to an endo-B-mannanase cloned from a | 2014-03-13 |
20140073549 | DETERGENT COMPOSITION COMPRISING PHOSPHINOSUCCINIC ACID ADDUCTS AND METHODS OF USE - Detergent compositions effective for controlling hard water scale accumulation are disclosed. Detergent compositions employing phosphinosuccinic acid and mono-, bis- and oligomeric phosphinosuccinic acid (PSO) derivatives with alkali metal carbonate and/or alkali metal hydroxide reduce had water scale accumulation on treated surfaces at alkaline conditions between about pH of 9 and 12.5. Methods employing the detergent compositions and preventing hard water scale accumulation are also provided. | 2014-03-13 |
20140073550 | SOLIDIFICATION MATRIX COMPRISING PHOSPHINOSUCCINIC ACID DERIVATIVES - Stability enhancement agents for use in a solidification matrices and solid detergent compositions are described. Stability enhancement is provided by a hydratable salt, water and phosphinosuccinic acid (PSO) derivative binding agents forming a dimensionally stable composition. Preferred phosphinosuccinic acid (PSO) derivatives include phosphinosuccinic acid and mono-, bis- and oligomeric phosphinosuccinic acid (PSO) derivatives. The stability enhancement composition for use in a solid detergent and solid detergent compositions are preferably biodegradable and substantially free of phosphate and NTA-free. | 2014-03-13 |
20140073551 | CLEANING COMPOSITIONS COMPRISING STRUCTURED PARTICLES - The present invention relates to a cleaning composition, preferably a granular detergent product, comprising a structured particle, preferably in an agglomerated form, comprising a cleaning active and a silica-based structurant having a hydrated particle size distribution of no more than 30 wt % greater than 45 micrometers and a tapped bulk density of from about 200 g/L to about 300 g/L. Process for preparing the structured particle, and methods of use, are also disclosed. | 2014-03-13 |
20140073552 | Subtilase Vairants - The present invention relates to enzymes produced by mutating the genes for a number of subtilases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved stability and/or improved wash performance in any detergent in comparison to their wild type parent enzymes. The enzymes are well-suited for use in any detergent and for some in especially liquid or solid shaped detergent compositions. | 2014-03-13 |
20140073553 | AMYLASE VARIANTS - The present invention relates to variants (mutants) of polypeptides, in particular Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits an alteration in at least one of the following properties relative to said parent alpha-amylase: substrate specificity, substrate binding, substrate cleavage pattern, thermal stability, pH/activity profile, pH/stability profile, stability towards oxidation, Ca | 2014-03-13 |
20140073554 | BUILDER GRANULES AND PROCESS FOR THEIR PREPARATION - A process for preparing builder granules suitable for use in a granular or tabletted detergent compositions, particularly for machine dishwash, involves forming a slurry of solid and aqueous MGDA Na3 spray dryer, under non-agglomerating conditions, to form spray dried particles comprising solid crystalline MGDA Na 3 dihydrate, compacting the spray dried particles into compacted aggregates and comminuting the compacted aggregates into granular particles to form builder granules having a particle size distribution suitable for use in a granular detergent composition. Prior to spray drying, the slurry is maintained at a slurry temperature of 20° or more for sufficient time for the resulting builder granules to remain free flowing after 48 hours storage at 20° C. and 65% relative humidity. The resulting granules, made by an efficient process, using conventional detergent manufacturing apparatus, exhibit excellent resistance to caking when damp and can be incorporated into granular detergent compositions or detergent tablets, such as machine dishwash compositions or tablets, without substantial degradation of flow or stickiness (for granular compositions) and without substantial reduction in friability or disintegration (for tabletted compositions). | 2014-03-13 |
20140073555 | USE OF MULTIVALENT SYNTHETIC LIGANDS OF SURFACE NUCLEOLIN FOR TREATING CANCER OR INFLAMMATION - A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising a support on which at least 3 pseudopeptide units are grafted, said compound being of formula (I). | 2014-03-13 |
20140073556 | Antagonists of the Interleukin-1 Receptor - The present invention discloses novel peptides derived from the IL-1 receptor antagonist protein (IL1 RA), capable of binding to the cell surface IL-1 receptor 1 (IL1 R1) and interfere with the binding of IL-1 to IL1 R1. This binding thus effectively antagonises the inflammatory effects of IL-1, such as by reducing TNF-alpha secretion from macrophages. This is of potential use as an anti-inflammatory factor throughout the human body, including the central nervous system. The use of said peptides as anti-inflammatory agents for treatment of pathological conditions wherein IL-1 plays a prominent role, such as inflammatory conditions of the body and the central nervous system, is thus an aspect of the present invention. | 2014-03-13 |
20140073557 | FGFRI-BASED ANTAGONISTS WITH IMPROVED GLYCOSAMINOGLYCAN AFFINITY AND METHODS OF USING SAME - A novel approach for inhibiting FGF2/FGFR1-mediated signalling is presented which is based on FGFR1 mutations to introduce higher affinity for the natural GAG co-receptors into the soluble part of the FGF1 receptor, preferably into the D2/D3 domains. Such recombinant drugs are expected to disrupt the natural FGF2/FGFR1/GAG triple complex by competing with the wtFGFR1 for GAG binding | 2014-03-13 |
20140073558 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS - The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against a variety of bacteria, including resistant strains. The compounds are useful as antibacterial agents against | 2014-03-13 |
20140073559 | Antibiotic Compositions for the Treatment of Gram Negative Infections - Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds. | 2014-03-13 |
20140073560 | CITROBACTER FREUNDII ANTIBACTERIAL AGENTS AND THEIR USE - Provided herein are methods for treating planktonic bacteria or a biofilm. The methods include contacting the planktonic bacteria or biofilm with an effective amount of an isolated | 2014-03-13 |
20140073561 | METHODS OF TREATING MEDICAL CONDITIONS USING PEPTIDES - The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. | 2014-03-13 |
20140073562 | NASAL DELIVERY - A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders. | 2014-03-13 |
20140073563 | FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME - The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas. | 2014-03-13 |
20140073564 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES - Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. | 2014-03-13 |
20140073565 | CXCR4 AND ROBO1 EXPRESSION AS MARKERS FOR AUTOIMMUNE DIABETES - CXCR4 and ROBO-1 are biomarkers associated with type 1 diabetes. Expression of CXCR4 and ROBO-1 in peripheral CD3 T cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients. Therapies are disclosed for reducing the progression of type 1 diabetes, and to reduce the risk of developing type 1 diabetes in patients who are at risk of developing type 1 diabetes. | 2014-03-13 |
20140073566 | METHODS OF USING CHIMERIC COILED-COIL MOLECULE - The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand. | 2014-03-13 |
20140073567 | USE OF PEGYLATED IGF-1 VARIANTS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS - The present invention relates to a pharmaceutical composition containing a PEGylated IGF-I variant derived from the wild-type human IGF-I amino acid sequence where one or two of the lysine amino acids at positions 27, 65, and 68 are altered to be a polar amino acid other than lysine and where the PEG is attached to at least one lysine residue. The invention also relates to methods for the treatment, prevention and/or delay of progression of neuromuscular disorders, in particular amyotrophic lateral sclerosis (ALS) by administering a therapeutically effective amount of the pharmaceutical composition of the invention. | 2014-03-13 |
20140073568 | ADMINISTRATION OF FGF9 FOR TREATMENT OF ANXIETY - The present invention provides methods for diagnosing mental disorders. The invention also provides methods of identifying modulators of mental disorders as well as methods of using these modulators to treat patients suffering from mental disorders. | 2014-03-13 |
20140073569 | METHOD FOR GENERATING IMMUNOMODULATORY CELLS, THE CELLS PREPARED THEREFROM AND USE THEREOF - The present invention develops a straightforward and rapid method for generating immunomodulatory cells from peripheral mononuclear cells, comprising treating peripheral mononuclear cells with a hepatocyte growth factor (HGF) to induce differentiation of the peripheral mononuclear cells into immunomodulatory leukocytes. The present invention also provides an immunomodulatory cell prepared according to this method. The present invention further provides a method for treating a disease caused by abnormal immune response comprising administering a HGF to a patient exhibiting the disease, inducing the patient's peripheral mononuclear cells to differentiate into immunomodulatory leukocytes, and modulating the abnormal immune response. | 2014-03-13 |
20140073570 | PHARMACEUTICAL COMPOSITION AND METHODS FOR PEPTIDE TREATMENT - Disclosed are compositions and methods for treating a patient with a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins, wherein the pharmaceutical composition is in the form of an emulsified nasal spray comprising: a macrocyclic permeation enhancer, a liquid carrier comprising water, and a therapeutically effective amount of a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins; wherein the macrocyclic permeation enhancer is a Hsieh enhancer emulsified in the liquid carrier. | 2014-03-13 |
20140073571 | Treatments for Gastrointestinal Disorders - The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. | 2014-03-13 |
20140073572 | TARGETING COMPLEMENT FACTOR H FOR TREATMENT OF DISEASES - The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion. | 2014-03-13 |
20140073573 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE - The invention provides compounds that are effective as inhibitors of human plasmin and plasma kallikrein, and that are useful for the prevention of blood loss and as components of fibrin adhesives. The invention further provides methods of making and using the compounds. | 2014-03-13 |
20140073574 | THERAPY FOR COMPLICATIONS OF DIABETES - A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ET | 2014-03-13 |
20140073575 | COLLAGEN HYDROXYLASES - Prolyl and lysyl hydroxylases isolated from Mimivirus are described. These are able to hydroxylate collagen. Isolated nucleic acids coding for the mentioned hydroxylases are incorporated into suitable vectors and used to express these hydroxylases in host cells, e.g. | 2014-03-13 |
20140073576 | METHODS OF PREVENTING OR TREATING BRAIN DISEASES - The present invention relates to methods for preventing or treating neurological diseases, particularly brain diseases, and improving cognitive functions using a composition comprising stanniocalcin 2 as an active ingredient. | 2014-03-13 |
20140073577 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 - Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7 and/or Nav1.3. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed. | 2014-03-13 |
20140073578 | Combination Therapy with Leukotoxin - The invention relates to pharmaceutical compositions comprising leukotoxin, a chemotherapeutic agent and a pharmaceutically acceptable carrier, including methods to treat cancer, and methods to induce apoptosis. | 2014-03-13 |
20140073579 | SMAC Mimetic - A SMAC mimetic and pharmaceutical compositions thereof and methods of use. | 2014-03-13 |
20140073580 | COMBINATIONS OF HDAC INHIBITORS AND PROTEASOME INHIBITORS - Provided herein are pharmaceutical agents, pharmaceutical compositions, methods of treatment, treatment regimens and kits for the treatment of cancer. | 2014-03-13 |
20140073581 | Hybrid Cyclic Libraries and Screens Thereof - Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits. | 2014-03-13 |
20140073582 | INSECTICIDE CRY PROTEINS OF BACILLUS THURINGIENSIS WITH ANTI-CANCER ACTIVITY - The invention relates to nucleic acid molecules encoding insecticidal proteins of the Cry family, derived from | 2014-03-13 |
20140073583 | STABLE COMPOSITIONS OF PEPTIDE EPOXY KETONES - The invention relates to pharmaceutical compositions that provide improved solubility and stability for peptide epoxy ketones. More specifically, the invention relates to pharmaceutical compositions comprising the peptide epoxy ketone proteasome inhibitor carfilzomib. | 2014-03-13 |
20140073584 | Thienopyranones as Kinase Inhibitors - The invention relates to compounds of formula I (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including inhibition of kinase activity such as PI-3 kinase. | 2014-03-13 |
20140073585 | PEPTIDE INHIBITORS OF HAUSP DEUBIQUITINASE - Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating ALL. | 2014-03-13 |
20140073586 | Compositions for the treatment of cancer, and methods for testing and using the same - A composition comprising leukotoxin proteins isolated from a bacterium is provided. In this composition, greater than 85% of the leukotoxin proteins are chemically modified at a basic amino acid residue, and the proteins induce cell death in myeloid leukocytes, while remaining substantially non-toxic to lymphoid leukocytes, lymphocytes, and red blood cells. Also provided is a method of selectively inducing cell death in myeloid leukocytes. The method comprises contacting the myeloid leukocytes with a composition comprising leukotoxin proteins. These leukotoxin proteins may be isolated from the NJ4500 strain of | 2014-03-13 |
20140073587 | RESISTANCE BIOMARKERS FOR HDAC INHIBITORS - Provided herein are methods for identifying a cancer patient at risk for resistance to an HDAC inhibitor therapy, comprising obtaining a tumor sample from the cancer patient; detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in the sample; quantifying a level of the TSPYL5 expression in the sample, wherein a high level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, correlates with resistance to the HDAC inhibitor therapy; and applying the correlation to identify the cancer patient at risk for resistance to the HDAC inhibitor therapy. Also provided is a method for identifying a cancer patient with an increased likelihood of a positive clinical response to an HDAC inhibitor therapy comprising obtaining a tumor sample from the cancer patient; detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in said sample; quantifying a level of said TSPYL5 expression in said sample, wherein a low level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, identifies said cancer patient with an increased likelihood of a positive clinical response to said HDAC inhibitor therapy. Related methods and compositions are also provided. | 2014-03-13 |
20140073588 | GLUE COMPOSITION FOR LUNG VOLUME REDUCTION - The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema. | 2014-03-13 |
20140073590 | Methods for Treating Pulmonary Hypertension - The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a reversible P2Y | 2014-03-13 |
20140073591 | MDR METHOD AND PRODUCTS FOR TREATING MRSA - Multidrug resistance reversers of the d-tetrandrine family are used in conjunction with penicillins and other principle drugs used to treat MRSA. | 2014-03-13 |
20140073592 | Ginkgo Derived Compositions And Their Use To Prevent Fruit Infestation by Codling Moth - Codling moth, | 2014-03-13 |
20140073593 | BRUTON'S TYROSINE KINASE AS ANTI-CANCER DRUG TARGET - Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells. | 2014-03-13 |
20140073594 | GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV - Compounds, compositions and methods are provided for use to inhibit infection by human immunodeficiency virus (HIV). More specifically, the present invention relates to glycomimetic compounds that inhibit HIV infection, and uses thereof. | 2014-03-13 |
20140073595 | AROMATIC AMIDES AS POTENTIATORS OF BIOEFFICACY OF ANTI-INFECTIVE DRUGS - The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical isomers or their dihydro or tetrahydro derivatives and an anti-infective drug useful in potentiating the bioefficacy of antiinfective drug. The combination of the present invention is useful in the treatment of certain infections and disease at lower concentration of anti-infectives necessary to inhibit the growth of microbial strains and may also find applications in reducing the resistance in microorganisms. | 2014-03-13 |
20140073596 | N-Pyrazole A2A Receptor Agonists - 2-adenosine N-pyrazole compounds having the following formula: | 2014-03-13 |
20140073597 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof - Disclosed are compounds, pharmaceutical compositions containing the compounds, uses of the compounds and compositions as modulators of histone methyltransferases, and methods for treating diseases influenced by modulation of histone methyltransferase activity. | 2014-03-13 |
20140073598 | MULTIPLE FOLATE FORMULATION AND USE THEREOF - A multiple folate composition having at least 3 different forms of folate comprising at least one of folic acid (a salt or ester thereof); at least one of a folinic acid (a salt or ester thereof); and at least one of a 5-methyl-tetrahydrofolic acid (a salt or ester thereof) is disclosed. The composition is useful as a nutritional supplement or medication in the treatment of folate deficiency and the sequella thereof and/or in conditions responsive to administration of metabolically useful folate. The compositions are particularly of use in patients who have impaired or reduced ability to convert folic acid to its metabolically active forms, and in the treatment of depression. | 2014-03-13 |
20140073599 | Plant Treatment Compositions and Methods for Their Use - Plant treatment compositions comprising metal alginate salts as compositions useful in the treatment of plants, particularly food crops. The metal alginate salts are found to be effective in the absence of herbicides, fungicides and pesticides. | 2014-03-13 |
20140073600 | FLUID COMPOSITIONS FOR IMPROVING SKIN CONDITIONS - The present specification discloses fluid compositions comprising a matrix polymer and stabilizing component, methods of making such fluid compositions, and methods of treating skin conditions in an individual using such fluid compositions. | 2014-03-13 |
20140073601 | METHOD FOR TREATING THE EAR, NOSE OR THROAT - Bodily tissue and structures may be protected using a fluid layer containing a mixture of chitosan and oxidized polysaccharide. The mixture forms a protective gel layer via in situ crosslinking. Compared to crosslinking using a low molecular weight aldehyde such as glutaraldehyde or genipin, oxidized polysaccharides appear to provide faster gelation while avoiding the use of potentially less bioacceptable low molecular weight aldehydes. | 2014-03-13 |
20140073602 | NITRIC OXIDE DELIVERING HYDROXYALKYL STARCH DERIVATIVES - The present invention relates to nitric oxide delivering hydroxyalkyl starch derivatives, methods of preparing the same, and specific uses of these hydroxyalkyl starch derivatives. | 2014-03-13 |
20140073603 | Phenylboronic Acid - The present invention relates to a specific phenylboronic acid compound having anti-cancer, anti-inflammatory, and anti-microbial activity, in addition to a pharmaceutical composition comprising the same. The present invention also discloses a process for preparing said compound. The compound is represented by the formula (I): | 2014-03-13 |
20140073604 | Ladder-Frame Polyether Conjugates - Disclosed are compounds that are conjugates of ladder frame polyether compounds and biologically active compounds or research compounds, pharmaceutical formulations comprising the conjugates, and methods of transporting the conjugates across biological membranes. | 2014-03-13 |
20140073605 | METHOD FOR THE REMOVAL AND CONTROL OF ARTHROPOD INFESTATION IN INTERIOR DWELLINGS - There is provided a method for the removal and control of arthropod infestation comprising the cleaning of surfaces and objects within an interior dwelling space using a high efficiency water extraction device, utilizing water that is heated to a temperature sufficient to kill the pest, and to which is added a cleaning agent comprising a surfactant that imparts a surface tension of between about 15 and about 30 dynes/cm, (a “super wetting agent”); in combination with application of an effective arthropod control composition to surfaces and objects within the interior dwelling spaces, the arthropod control composition comprising an arthropod control agent and a surfactant that imparts a surface tension of below about 30 dynes/cm. | 2014-03-13 |
20140073606 | 2'-FLUORO-6'-METHYLENE CARBOCYCLIC NUCLEOSIDES AND METHODS OF TREATING VIRAL INFECTIONS - The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially HBV. | 2014-03-13 |
20140073607 | COMPOUNDS FOR USE IN THE TREATMENT OF FELINE RETROVIRAL INFECTIONS - The present invention relates to compounds and compositions for use in the treatment or prevention of retroviral infections in felines, in particular cats, and to the use of said derivatives for the manufacture of a medicament for the treatment or prevention of feline leukemia virus (FeLV) infections occurring alone or together with feline immunodeficiency virus (FIV) infections in cats. | 2014-03-13 |
20140073608 | Butyrylcholinesterase Inhibitors - Butyrylcholinesterase inhibitors, their formulation, and their use primarily in the treatment of neurodegenerative diseases. These inhibitors generally are phosphates, phosphonates, phosphinates, and phosphoramidates. | 2014-03-13 |
20140073609 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation - Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3. | 2014-03-13 |
20140073610 | AROMATIC CARBOXYLIC ACID DERIVATIVES FOR TREATMENT AND PROPHYLAXIS OF GASTROINTESTINAL DISEASES INCLUDING COLON CANCERS - Prodrug compounds which metabolize into 5-ASA or analogs thereof, and taurine or analogs thereof, in the colon site are disclosed. Pharmaceutical compositions including the compounds, and methods of treatment using the compounds, are also disclosed. Such compounds have utility for treating or preventing gastrointestinal disorders, including colon cancer, ulcerative colitis and Crohn's disease. | 2014-03-13 |
20140073611 | METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM - The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease. | 2014-03-13 |
20140073612 | TRANSDERMAL DELIVERY SYSTEM KIT - A transdermal delivery kit that enhances the efficacy of a topical drug includes at least one drug dispensing device, a lipophilic base, a hydrophilic base, a lipid-soluble active ingredient, a water-soluble active ingredient, a first container for mixing the lipophilic base with the lipid-soluble active ingredient to form a first compound, a second container for mixing the hydrophilic base with the water-soluble active ingredient to form a second compound, a mixing member, and instructions for compounding the lipophilic base with the lipid-soluble active ingredient to form the first compound, compounding the hydrophilic base with the water-soluble active ingredient to form the second compound, and mixing the first compound and the second compound to form a transdermal pharmaceutical delivery system capable of delivering a drug to the dermal layer of the skin. | 2014-03-13 |
20140073613 | TOPICAL FORMULATION FOR TREATMENT OF HYPERKERATOTIC SKIN - The present invention relates in general to topical compositions having improved antimicrobial effect useful for the treatment of hyperkeratotic skin conditions. More specifically, the present invention relates to topical compositions comprising a combination of one or more alfa-hydroxy acids, urea, glycerol, and panthenol, as well as the use of such compositions for the treatment of hyperkeratotic skin conditions, in particular on the feet, and also on other body areas where thick skin is noted and where infections should be avoided. | 2014-03-13 |
20140073614 | PHARMACEUTICAL AND FOOD COMPOSITIONS FOR PREVENTING OR TREATING DIABETES OR OBESITY - The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the | 2014-03-13 |
20140073615 | Treatment of Psoriasis - A lipid layer forming composition for topical treatment of psoriasis comprises volatile silicone oil, polar lipid, C | 2014-03-13 |
20140073616 | HYDROCORTISONE NANOTECHNOLOGICAL DELIVERY SYSTEM - A composition is provided having nano technological delivery of a medicament through the skin. The composition contains hydrocortisone, resveratrol and a sulfate free surfactant. The composition is formulated into a shampoo and the shampoo facilitates nano technological delivery of the hydrocortisone and the resveratrol through the skin of a user. | 2014-03-13 |
20140073617 | PANAXADIOL-CONTAINING COMPOSITION - A panaxadiol-containing composition, containing: panaxadiol; and at least one of sucrose fatty acid ester and lecithin. | 2014-03-13 |
20140073618 | CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS AND METHODS OF TREATMENT - This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder. | 2014-03-13 |
20140073619 | METHOD FOR TREATING CHRONIC PAIN - The present invention provides analgesic compounds comprising at least one modified metalloporphyrin compound. Also provided are methods of treating pain by orally administering an analgesic compounds comprising at least one modified metalloporphyrin compound. | 2014-03-13 |
20140073620 | VEGFR3 INHIBITORS - This invention relates to a compound of the formula (I): | 2014-03-13 |
20140073621 | 5-ALKYNYL-PYRIMIDINES - The present invention encompasses compounds of general formula (1) | 2014-03-13 |
20140073622 | IMIDAZOLE CARBONYL COMPOUND - To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient. | 2014-03-13 |
20140073623 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same - The invention provides tricyclic sulfonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 2014-03-13 |
20140073624 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same - The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at least one heterocylic moiety that are useful as such agents. | 2014-03-13 |
20140073625 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS - Compounds of general Formula (I), and compositions comprising compounds of general formula I that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 2014-03-13 |
20140073626 | AZAINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS - The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts. | 2014-03-13 |
20140073627 | BRADYKININ B1 ANTAGONISTS - The invention relates to compounds of formula (I) | 2014-03-13 |
20140073628 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE - The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula I and pharmaceutically acceptable salts thereof, wherein the variables are as defined herein. | 2014-03-13 |
20140073629 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS - The present invention relates to compounds of formula (I): | 2014-03-13 |
20140073630 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS - This invention provides novel pharmaceutical compositions of the compound of formula (I): | 2014-03-13 |
20140073631 | ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS - Disclosed are guanidine and biguanidine derivatives which have anti-viral and antibacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds. Methods of treating infections using the guanidine and biguanidine derivatives are also disclosed. | 2014-03-13 |
20140073632 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS - Novel CFTR corrector compounds that are effective in rescuing halide efflux in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of screening for CFTR corrector compounds are also described herein. The methods of screening include contacting a cell that endogenously expresses a CFTR mutation with the compound to be screened and detecting a rescue of halide efflux from the cell. | 2014-03-13 |
20140073633 | INHIBITORS OF THE SHIGA TOXINS TRAFFICKING THROUGH THE RETROGRADE PATHWAY - The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins. | 2014-03-13 |
20140073634 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases. | 2014-03-13 |